These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

212 related items for PubMed ID: 8817593

  • 1. Ketamine in cancer pain: an update.
    Mercadante S.
    Palliat Med; 1996 Jul; 10(3):225-30. PubMed ID: 8817593
    [Abstract] [Full Text] [Related]

  • 2. Prolonged analgesic effect of ketamine, an N-methyl-D-aspartate receptor inhibitor, in patients with chronic pain.
    Rabben T, Skjelbred P, Oye I.
    J Pharmacol Exp Ther; 1999 May; 289(2):1060-6. PubMed ID: 10215688
    [Abstract] [Full Text] [Related]

  • 3. The use of ketamine as adjuvant therapy to control severe pain.
    Campbell-Fleming JM, Williams A.
    Clin J Oncol Nurs; 2008 Feb; 12(1):102-7. PubMed ID: 18258579
    [Abstract] [Full Text] [Related]

  • 4. [Low doses ketamine: antihyperalgesic drug, non-analgesic].
    Richebé P, Rivat C, Rivalan B, Maurette P, Simonnet G.
    Ann Fr Anesth Reanim; 2005 Feb; 24(11-12):1349-59. PubMed ID: 16115745
    [Abstract] [Full Text] [Related]

  • 5. [The role of the NMDA-receptor blocker and stimulator ketamine and glycine in the development of a neuropathic pain syndrome].
    Danilova EI, Grafova VN, Reshetniak VK.
    Eksp Klin Farmakol; 1997 Feb; 60(4):10-3. PubMed ID: 9376747
    [Abstract] [Full Text] [Related]

  • 6. Low dose ketamine: a therapeutic and research tool to explore N-methyl-D-aspartate (NMDA) receptor-mediated plasticity in pain pathways.
    Chizh BA.
    J Psychopharmacol; 2007 May; 21(3):259-71. PubMed ID: 17591654
    [Abstract] [Full Text] [Related]

  • 7. Ultra-low dose ketamine and memantine treatment for pain in an opioid-tolerant oncology patient.
    Grande LA, O'Donnell BR, Fitzgibbon DR, Terman GW.
    Anesth Analg; 2008 Oct; 107(4):1380-3. PubMed ID: 18806055
    [Abstract] [Full Text] [Related]

  • 8. [Development of opioid tolerance -- molecular mechanisms and clinical consequences].
    Freye E, Latasch L.
    Anasthesiol Intensivmed Notfallmed Schmerzther; 2003 Jan; 38(1):14-26. PubMed ID: 12522725
    [Abstract] [Full Text] [Related]

  • 9. Ketamine as an adjuvant for treatment of cancer pain in children and adolescents.
    Finkel JC, Pestieau SR, Quezado ZM.
    J Pain; 2007 Jun; 8(6):515-21. PubMed ID: 17434801
    [Abstract] [Full Text] [Related]

  • 10. Intrathecal antinociceptive interaction between the NMDA antagonist ketamine and the opioids, morphine and biphalin.
    Kosson D, Klinowiecka A, Kosson P, Bonney I, Carr DB, Mayzner-Zawadzka E, Lipkowski AW.
    Eur J Pain; 2008 Jul; 12(5):611-6. PubMed ID: 18068383
    [Abstract] [Full Text] [Related]

  • 11. Interindividual differences in the analgesic response to ketamine in chronic orofacial pain.
    Rabben T, Øye I.
    Eur J Pain; 2001 Jul; 5(3):233-40. PubMed ID: 11558979
    [Abstract] [Full Text] [Related]

  • 12. The antiallodynic effect of NMDA antagonists in neuropathic pain outlasts the duration of the in vivo NMDA antagonism.
    Christoph T, Schiene K, Englberger W, Parsons CG, Chizh BA.
    Neuropharmacology; 2006 Jul; 51(1):12-7. PubMed ID: 16616769
    [Abstract] [Full Text] [Related]

  • 13. NMDA receptor antagonists and pain: ketamine.
    Muir WW.
    Vet Clin North Am Equine Pract; 2010 Dec; 26(3):565-78. PubMed ID: 21056300
    [Abstract] [Full Text] [Related]

  • 14. The role of ketamine in pain management.
    Visser E, Schug SA.
    Biomed Pharmacother; 2006 Aug; 60(7):341-8. PubMed ID: 16854557
    [Abstract] [Full Text] [Related]

  • 15. Ketamine potentiates analgesic effect of morphine in postoperative epidural pain control.
    Wong CS, Liaw WJ, Tung CS, Su YF, Ho ST.
    Reg Anesth; 1996 Aug; 21(6):534-41. PubMed ID: 8956390
    [Abstract] [Full Text] [Related]

  • 16. Combined opioid-NMDA antagonist therapies. What advantages do they offer for the control of pain syndromes?
    Wiesenfeld-Hallin Z.
    Drugs; 1998 Jan; 55(1):1-4. PubMed ID: 9463786
    [Abstract] [Full Text] [Related]

  • 17. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
    Pergolizzi J, Böger RH, Budd K, Dahan A, Erdine S, Hans G, Kress HG, Langford R, Likar R, Raffa RB, Sacerdote P.
    Pain Pract; 2008 Jan; 8(4):287-313. PubMed ID: 18503626
    [Abstract] [Full Text] [Related]

  • 18. A review of the use of ketamine in pain management.
    Tawfic QA.
    J Opioid Manag; 2013 Jan; 9(5):379-88. PubMed ID: 24353050
    [Abstract] [Full Text] [Related]

  • 19. Effects of ketamine on acute somatic nociception in wild-type and N-methyl-D-aspartate (NMDA) receptor epsilon1 subunit knockout mice.
    Petrenko AB, Yamakura T, Askalany AR, Kohno T, Sakimura K, Baba H.
    Neuropharmacology; 2006 May; 50(6):741-7. PubMed ID: 16427663
    [Abstract] [Full Text] [Related]

  • 20. An intravenous ketamine test as a predictive response tool in opioid-exposed patients with persistent pain.
    Cohen SP, Wang S, Chen L, Kurihara C, McKnight G, Marcuson M, Mao J.
    J Pain Symptom Manage; 2009 Apr; 37(4):698-708. PubMed ID: 18789637
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.